Fernandez cites Biocon, Cipla, Divi’s Labs and Sun Pharma for plans to launch liraglutide in the U.S. and other markets. They ...
Sun Pharmaceutical Industries is developing ... entered the space in 2024 with the launch of Lirafit, a biosimilar of liraglutide. Meanwhile, Biocon has received authorisation to market a generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results